Apogee Therapeutics, Inc. (APGE)

53.22 +0.30 (+0.57%) At close: 04:00PM EDT

Apogee Therapeutics, Inc.

221 Crescent Street
Building 17 Suite 102b
Waltham, MA 02453
United States
650-394-5230
https://www.apogeetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 91

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Thomas Henderson M.D.	CEO & Director	1.17M	N/A	1990
Ms. Jane Pritchett V. Henderson	Chief Financial Officer	843.64k	N/A	1966
Dr. Carl Linden Dambkowski M.D.	Chief Medical Officer	870.83k	N/A	1986
Ms. Noel Kurdi	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Matthew Batters J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1976
Ms. Emily Cox	VP & Head of People	N/A	N/A	N/A
Dr. Rebecca Dabora Ph.D.	Chief Development Officer	N/A	N/A	1960
Ms. Wendy Aspden-Curran	Senior Vice President of Clinical Operations	N/A	N/A	N/A
Dr. Drew Badger Ph.D.	Senior VP and Head of Regulatory Affairs & Toxicology	N/A	N/A	N/A
Ms. Monica Forbes	Senior Vice President of Finance	N/A	N/A	1976

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Corporate governance

Apogee Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.